SCHEDULE: Adage Capital Discloses 3.96% Stake in Zevra Therapeutics
Beneficial Ownership Disclosure (Amendment)
Adage Capital Management, L.P. and its principals have filed an amended Schedule 13G, reporting a 3.96% beneficial ownership stake in Zevra Therapeutics, Inc. as of September 30, 2025.
Summary
- Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross (collectively, the "Reporting Persons"), reported beneficial ownership of 2,225,000 shares of Zevra Therapeutics, Inc. common stock.
- This ownership represents 3.96% of the company's outstanding common stock.
- The percentage is calculated based on an aggregate of 56,135,091 shares of Common Stock outstanding as of August 8, 2025, as reported in the company's Quarterly Report on Form 10-Q.
- The Reporting Persons hold shared voting power and shared dispositive power over all 2,225,000 beneficially owned shares.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating a previous filing existed.
- The securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of Zevra Therapeutics, Inc.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of beneficial ownership by an institutional investor, indicating a stake of 3.96% in Zevra Therapeutics, Inc. It does not contain information that would significantly alter the sentiment, as it is a compliance filing rather than a performance or strategic announcement.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, which is now below the 5% threshold for mandatory reporting.
- Market: Offers insight into institutional holdings, potentially influencing market perception of the stock's institutional support.
Key Dates
| Date | Description |
|---|---|
| 2025-08-08 | Date as of which 56,135,091 shares of Common Stock were outstanding, used for percentage calculation, as reported in the company's Form 10-Q. |
| 2025-08-12 | Date Zevra Therapeutics, Inc. filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025. |
| 2025-09-30 | Date of the event which required the filing of this statement (beneficial ownership status). |
| 2025-11-13 | Date the Schedule 13G Amendment No. 1 was signed by the Reporting Persons. |
Keywords
Zevra Therapeutics, Adage Capital Management, Beneficial Ownership, Schedule 13G, Institutional Investor, Common Stock, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.